Meeting
2021 ASCO Annual Meeting
Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.
Authors
Katy K. Tsai
University of California, San Francisco, San Francisco, CA
Katy K. Tsai , Iwei Yeh , Adil Daud , Ari Oglesby
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04598009
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9594)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9594
Abstract #
TPS9594
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2023 ASCO Annual Meeting
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
First Author: Lili Mao
Poster
2022 ASCO Annual Meeting
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Lisa A. Kottschade
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela